ID   HeLa IFITM1/2/3-KO
AC   CVCL_B0A4
SY   IFITM1/2/3 Knockout; C5-9
DR   ATCC; CRL-3452
DR   Wikidata; Q108820452
RX   PubMed=30643282;
CC   Population: African American.
CC   Characteristics: Facilitates the functional analysis of IFITMs and as well as their mechanisms of regulation. Can also be used to identify other innate immunity factors and/or screen for new anti-infective drug candidates (ATCC=CRL-3452).
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 5412; IFITM1.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3.
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3
ST   D16S539: 9,10
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0030 ! HeLa
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=30643282; DOI=10.1038/s41589-018-0213-2;
RA   Spence J.S., He R.-N., Hoffmann H.-H., Das T., Thinon E., Rice C.M.,
RA   Peng T., Chandran K., Hang H.C.;
RT   "IFITM3 directly engages and shuttles incoming virus particles to
RT   lysosomes.";
RL   Nat. Chem. Biol. 15:259-268(2019).
//